Member Info for Bluebelly

Expected news not imminent. But expect the unexpected.
There could be a few II’s just under 3% now we are FTSE listed.

And cheap.

BB

StarKnight: There was a lot of confusion early on in the year and people stating therewas no ex-date for TLSA holders, along with the fact that the Nasdaq has different rules to the FTSE, hence the 'Potmess' we have witnessed play out.

BB

A small point:
30th Oct 20 was a Friday, so if you sold or bought on Fri 30th Oct, the Accustem belong to the Buyers, them being the holder on Mon 2nd Nov 20.

BB

Ex-entitlement date was the 2nd Nov 20 for UK shares.
Record Date: 07:00 on 30th Oct 20
From RNS: 'Shareholders are reminded that unless the counterparties specifically agree otherwise, a buyer of the Company's Ordinary Shares ahead of the Ex-Date will assume the benefit to the Demerged Shares, and a seller, ahead of the Ex-Date, would need to pass the benefit to the buyer, even if the seller is the recorded owner at the Record Date.'

BB

News could arrive anytime on:
Strategic Initiative with Takanawa Japan K.K., Pharma Team, to Identify a Partner in Japan and Other Asian Countries for Further Clinical Development of Milciclib in Patients with Advanced Hepatocellular Carcinoma.
Q4 or Q1 22:
The first patient with SPMS was dosed on May 24, 2021 with nasally administered Foralumab. The treatment regimen will continue for six months to examine long-term safety, tolerability and clinical responses.
Oct 21: Trial starts:-
Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody.

BB

I understood that the buy out of the other company included trained staff, equipment and it was already generating a profit.

BB

It's here: Page 2
https://ir.tizianalifesciences.com/static-files/0bae55ef-6589-43f2-a4bd-65be16b3dce1
'As we have stated previously, Accustem may be publicly listed upon completion of the spinout; its valuation could be fairly reckoned at $280M—10% of the
valuation placed upon Genomic Health at the time of its acquisition by EXACT Sciences.'

BB

I believe it was one of the Broker notes. Basically, they gave a value for Accustem, stating Oncotype DX sold for $2.8B and Accustem could start around 10% of that at £200m with a future value in excess of Oncotype, but there is a lot to progress before that.

BB

Wisha as you say, it may trade on the OTC pinks for a while . This is unfortunate for a lot of holders in the UK , because if your TILS were held in an ISA, then you would expect the Accustem to remain in your ISA tax free wrapper, however the Pinks are not allowed in an ISA. . This raises a few questions:
1. How do you work out you profit & loss for self assessment if not held in an ISA when you sell them?
2. Would I have to pay tax if they were valued at £1 and I sold my 30,000 shares, my TILS are in an ISA for a reason, Accustem was included in TILS in that ISA.
2. Could they remain in an ISA for a few weeks if a Nasdaq listing is announced for Q4 or next year?

Lets hope it's been moved out of TILS to sell quickly and that we receive a cash settlement in place of the shares whilst still held in an ISA.

BB

Thanks for the reply and clarifying what I thought Sharebel.
The price does seem cheap, but not sure I'll be buying any just yet.

BB

I understand that the OTC pinks are not reflective of the Accustem worth. The question that needs to be addressed is.
Is the price quoted on the pinks for 1 ADR, that represents two Accustem shares. Or - is it for for 1 Accustem share.
Fom this link there is no mention of the Ticker: ACMSY on the document.
https://www.sec.gov/Archives/edgar/data/0001850767/000138713121006805/accu-f6_062221.htm
However this link does:
https://www.sec.gov/edgar/browse/?CIK=1850767&owner=exclude
'AccuStem Sciences Ltd ACMSY on OTC'.

Hence, I believe the price quoted is for two Accustem shares = 1 ADR - Currently $0.46 / 2 / 1.38 = 16.6p
However as mentioned earlier, I don't believe this reflects the pricing that Accustem will see when it is properly traceable by all holders.

BB

https://www.sec.gov/Archives/edgar/data/0001850767/000138713121006805/accu-f6_062221.htm
From the attached link:
American Depositary Shares evidenced by American Depositary Receipts, each American Depositary Share representing two ordinary shares of Accustem Sciences Limited.

Therefore I believe: 1 Tils share gave you 1 Accustem share - 2 Accustem shares gives you 1 ADR.
16p in my book!

BB

II distributed them a few weeks ago in my ISA!!

BB

I'd be happy with that! Especially if I'd bought via TLSA on the 8th July.
Madness

BB

Mine wasn't, I just got the share allocation :-)

You have to be on the same wave length!!

BB

If you bought in November roger65, you will probably have a lower average than I @ 130p, my only consolation is I will get Accustem shares one day, your only consolation is you know where you stand in respect of your portfolio value.

BB

My shares in Accustem have been showing for a while, so I cannot complain in that respect, but people are still missing their allocation and that is wrong. By people complaining, it will hopefully put some pressure on the company to at least update the holders and give some target dates for the way ahead.

BB

Even the four warning signs are things that have already happened in the past. The market is meant to be forward looking. That's just for other FTSE listed stocks, TILS have to earn the right for that luxury.

BB

Markygee:@bluebelly didn't the bod recently say they'd give regular updates? Or did i imagine that?
It rings a bell that they did mention improved Comms, or regular updates. However they probably meant via the media channels, which has shown previously to do nothing for the SP. An updated presentation with the expected time frames would be a good start.
Are you listening Dr. Kevin Schutz, Vice-President of Regulatory Affairs?
You've had over six weeks to get your feet under the table. May be he's found a lot of issues with previous Regulatory affairs, or a lack of!!!

BB

Over the last 12 months we have had many RNS's every month (Excluding the Price monitoring Extensions). We have now had six weeks with no TILS relevant news.

BB